Literature DB >> 19176318

FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.

Aude Magerus-Chatinet1, Marie-Claude Stolzenberg, Maria S Loffredo, Bénédicte Neven, Catherine Schaffner, Nicolas Ducrot, Peter D Arkwright, Brigitte Bader-Meunier, José Barbot, Stéphane Blanche, Jean-Laurent Casanova, Marianne Debré, Alina Ferster, Claire Fieschi, Benoit Florkin, Claire Galambrun, Olivier Hermine, Olivier Lambotte, Eric Solary, Caroline Thomas, Francoise Le Deist, Capucine Picard, Alain Fischer, Frédéric Rieux-Laucat.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is characterized by splenomegaly, lymphadenopathy, hypergammaglobulinemia, accumulation of double-negative TCRalphabeta(+) CD4(-)CD8(-) T cells (DNT cells), and autoimmunity. Previously, DNT cell detection and a functional defect of T cells in a FAS-induced apoptosis test in vitro had been used for ALPS diagnosis. However, a functional defect can also be detected in mutation-positive relatives (MPRs) who remain free of any ALPS-related disease. In contrast, lymphocytes from patients carrying a somatic mutation of FAS exhibit normal sensitivity to FAS-induced apoptosis in vitro. We assessed the soluble FAS-L concentration in the plasma of ALPS patients carrying FAS mutations. Overall, we showed that determination of the FAS-L represents, together with the IL-10 concentration and the DNT cell percentage, a reliable tool for the diagnosis of ALPS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176318     DOI: 10.1182/blood-2008-09-179630

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

3.  Autoimmune lymphoproliferative syndrome: a multifactorial disorder.

Authors:  Frédéric Rieux-Laucat; Aude Magerus-Chatinet
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

4.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Authors:  Julie E Niemela; Lianghao Lu; Thomas A Fleisher; Joie Davis; Iusta Caminha; Marc Natter; Laurel A Beer; Kennichi C Dowdell; Stefania Pittaluga; Mark Raffeld; V Koneti Rao; João B Oliveira
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

5.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

6.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

Review 7.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

8.  New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children.

Authors:  Nathalie Aladjidi; Guy Leverger; Thierry Leblanc; Marie Quitterie Picat; Gérard Michel; Yves Bertrand; Brigitte Bader-Meunier; Alain Robert; Brigitte Nelken; Virginie Gandemer; Hélène Savel; Jean Louis Stephan; Fanny Fouyssac; Julien Jeanpetit; Caroline Thomas; Pierre Rohrlich; André Baruchel; Alain Fischer; Geneviève Chêne; Y Perel
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

9.  Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.

Authors:  Christian Klemann; Myrian Esquivel; Aude Magerus-Chatinet; Myriam R Lorenz; Ilka Fuchs; Nathalie Neveux; Martin Castelle; Jan Rohr; Claudia Bettoni da Cunha; Martin Ebinger; Robin Kobbe; Bernhard Kremens; Florian Kollert; Eleonora Gambineri; Kai Lehmberg; Markus G Seidel; Kathrin Siepermann; Thomas Voelker; Volker Schuster; Sigune Goldacker; Klaus Schwarz; Carsten Speckmann; Capucine Picard; Alain Fischer; Frederic Rieux-Laucat; Stephan Ehl; Anne Rensing-Ehl; Benedicte Neven
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941

10.  The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review.

Authors:  Rohan Ameratunga; See-Tarn Woon; Katherine Neas; Donald R Love
Journal:  Allergy Asthma Clin Immunol       Date:  2010-06-08       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.